Income Statement
INMED PHARMACEUTICALS INC.
INM
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Jun 30, 2025 2025 FY | Jun 30, 2024 2024 FY | Jun 30, 2023 2023 FY | Jun 30, 2022 2022 FY | Jun 30, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
4.94 | 4.60 | 4.14 | 5.20 | - |
|
Cost of Revenue
|
3.24 | 3.50 | 2.42 | 0.55 | - |
|
Gross Profit
|
1.71 | 1.10 | 1.40 | 0.54 | - |
|
Operating Expenses
|
9.65 | 9.30 | 9.78 | 17.81 | 9.94 |
|
Research & Development
|
2.85 | 3.77 | 3.73 | 7.28 | 5.34 |
|
Selling, General & Administrative
|
6.56 | 5.25 | 5.85 | 6.87 | 4.48 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-7.95 | -8.20 | -8.38 | -17.26 | -9.94 |
|
Non-Operating Income
|
0.22 | 0.53 | -0.44 | - | - |
|
Interest Income
|
0.16 | 0.53 | 0.49 | 0.10 | 0.02 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | 0.43 | - | -0.36 |
|
Income Before Tax
|
8.69 | 0.20 | -7.93 | - | - |
|
Income Tax Expense
|
0.00 | 0.01 | 0.01 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-8.16 | -7.68 | -7.95 | -18.60 | -10.20 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Jun 30, 2025 2025 FY | Jun 30, 2024 2024 FY | Jun 30, 2023 2023 FY | Jun 30, 2022 2022 FY | Jun 30, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-7.73 | -7.98 | -8.18 | -17.08 | -9.82 |
|
Earnings Per Share (Basic)
|
-8.36 | -1.01 | -3.25 | -33.17 | - |
|
Diluted EPS
|
-8.36 | - | - | - | - |
|
Weighted Average Shares
|
0.98 | 7.62 | 2.45 | 0.56 | - |
|
Diluted Weighted Avg Shares
|
0.98 | - | - | 0.56 | 6.72 |
|
Comprehensive Income
|
- | - | - | -18.60 | -9.77 |